Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib + Ceritinib in Unresectable Melanoma
NCT03501368Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceritinib in melanoma, sponsored by Moffitt Cancer Center. Primary endpoints: Maximum Tolerated Dose up to 12 months, Recommended Phase 2 Dose up to 12 months and 1 more. Started Jun 2018; status: completed.
02
Drugs
ceritinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03501368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03501368.